University Of Pittsburgh Scientist Discovers How A Novel Vitamin K Stops Cancer Cell Growth

June 01, 1998

PITTSBURGH, June 1 -- Scientists at the University of Pittsburgh have discovered how a novel form of vitamin K exerts its cancer-killing effects in primary liver cancers, which are notoriously resistant to chemotherapy. The research results, published in the May issue of The Journal of Biological Chemistry, describe an important new way to treat, and possibly prevent, cancer by triggering programmed cell death.

"Our finding is extremely important if we are to maximize the use of vitamin K compounds against cancer," noted Brian Carr, M.D., Ph.D., FRCP, professor of surgery in the Thomas E. Starzl Transplantation Institute and director of the Liver Cancer Center at the University of Pittsburgh Cancer Institute (UPCI). "Through our ongoing research, we now know that the vitamin K compounds not only can kill liver cancers, but also can destroy other types of cancer in tissue cultures, including breast cancer and melanoma. They do so by a quite novel growth-regulating mechanism."

"One of the attractive features of this unique compound is that it appears to stop cancer cell growth without producing toxicity. We now are testing this compound against cancers in rats, and given positive results, we hope to begin clinical trials of this agent within two years."

The Pitt research team found that a vitamin K analog, Compound 5 (Cpd 5), causes an imbalance in the normal activity of enzymes that control the addition or removal of small molecules called phosphate groups from selected proteins inside cells. Specifically, Cpd 5 blocks the activity of enzymes called protein-tyrosine phosphatases, which normally remove phosphate groups from selected proteins inside liver cancer cells. However, Cpd 5 does not interfere with another group of enzymes called protein tyrosine-kinases, which add phosphate groups to these same proteins. The result is an excess of what are called tyrosine phosphorylated proteins, which trigger a variety of activities within cells. They exert anti-cancer effects by inducing the shutdown and subsequent death of a cell, commonly referred to as programmed cell death.

Liver cancer is thought to be one of the three commonest cancers worldwide. The disease caused about 15,000 U.S. deaths in 1997 alone. Major causes of this cancer include infection with either hepatitis B or C or chronic alcohol consumption. In the United States and other developed countries, liver cancer may be treated by taking out the area of the liver containing a tumor or by surgically removing the diseased organ and transplanting a new one. However, liver transplantation is costly and often unavailable due to the scarcity of donated organs, or due to the advanced nature of the cancer at diagnosis.

"By providing this modified vitamin K to individuals at known risk of developing liver cancer, we might be able to reduce the incidence of this devastating illness. By treating liver cancer with this agent, we possibly could remove some individuals with this disease from transplant waiting lists, if it is as effective in humans as it is experimentally," said Dr. Carr.

Dr. Carr and his colleagues recently reported that Cpd 5 can inhibit liver regeneration in rats that had part of their livers removed. The animals suffered no toxic side effects.

Researchers at UPCI are at the forefront of experimental work using vitamins A, D and K to prevent and treat various forms of cancer in laboratory animals and in clinical trials with patients. As one of 31 National Cancer Institute-designated comprehensive cancer centers, UPCI is recognized for its interdisciplinary approach to cancer prevention, detection, diagnosis, treatment, education and community outreach and for its commitment to translational research that brings new cancer therapies from the laboratory bench to the patient's bedside as rapidly as possible.

The new vitamin K is not in clinical testing at this time. However, patients and physicians can contact the UPCI's Cancer Information and Referral Service for more information about cancer and ongoing clinical trials by calling 1 (800) 237-4PCI(4724) or (412) 624-1115. Inquirers also can visit UPCI's website at

University of Pittsburgh Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to